Second death in Novartis gene therapy trials under investigation

(Reuters) – Novartis AG, which this week announced positive interim trial results for its experimental gene therapy for spinal muscular atrophy, on Friday said investigation is underway into whether a second trial death could be related to the treatment.

The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland January 25, 2017. REUTERS/Arnd Wiegmann

Novartis has filed for U.S. Food and Drug Administration approval of the gene therapy, Zolgensma, and a decision is expected within weeks. The FDA submission was based on findings from a trial of 15 babies treated with Zolgensma.

But Novartis has expanded its clinical trial program – presenting on Tuesday at an Orlando, Florida meeting of the Muscular Dystrophy Association interim results for 22 babies with Type 1 SMA, the most serious form of the disease. The data showed that Zolgensma treatment resulted in encouraging progress in motor skills such as the ability to sit up. One patient died from respiratory failure, which was deemed by the investigator and an independent monitor to be unrelated to the gene therapy.

SMA, which can lead to paralysis, breathing difficulty and death, is the leading genetic cause of death in infants.

Novartis officials also disclosed that in addition to that death, a 6-month-old patient with Type 1 SMA had recently died after undergoing Zolgensma treatment in the company’s European trial.

“Preliminary findings indicate this occurred in the context of a severe respiratory infection followed by neurological complications in a symptomatic SMA Type 1 patient, and was deemed possibly related to treatment by the investigator,” Novartis spokesman Eric Althoff said in an emailed statement on Friday.

He said an autopsy has been performed and results are pending. Meanwhile, trial investigators and regulatory authorities have been informed.

Gene therapies use engineered viruses to carry healthy genetic material into a person’s cells to replace faulty or mutated genes that cause a disease or condition. Zolgensma

“As we learn more, we will provide further updates,” Althoff said.

Novartis estimates that without treatment, 50 percent of babies with SMA Type 1 will not survive or will need permanent breathing support by the time they are 10.5 months old.

The company has said its price for Zolgensma will be determined in negotiations with health plans, but it believes the gene therapy would be cost effective at $4 million to $5 million as a one-time treatment.

Reporting By Deena Beasley; Editing by Marguerita Choy

Source

more recommended stories

  • Novartis has 25 blockbusters in the pipeline: CEO

    FILE PHOTO: Logo of Swiss drugmaker.

  • Senator Gillibrand wants insurance to pay for fertility treatments

    WASHINGTON (Reuters) – U.S. Democratic presidential.

  • Hundreds rally at U.S. Supreme Court, calling state abortion bans as step backward

    WASHINGTON (Reuters) – Abortion-rights campaigners, including.

  • French court says doctors must resume life support for paralyzed patient

    STRASBOURG, France (Reuters) – A French.

  • Missouri follows Alabama by passing restrictive abortion bill

    (Reuters) – Missouri lawmakers passed a.

  • Too much screen time tied to school problems even in little kids

    (Reuters Health) – Kindergarteners who get.

  • Smokers have higher risk for multiple strokes

    (Reuters Health) – Smokers who have.

  • Missouri assembly passes restrictive abortion bill, days after Alabama

    (Reuters) – The lower house of.

  • Missouri Senate passes bill to ban abortions after eight weeks

    (Reuters) – Missouri’s Senate passed a.

  • Alabama governor signs strictest U.S. abortion ban into law

    (Reuters) – Alabama’s governor signed a.

  • Alabama Senate bans nearly all abortions, including rape cases

    (Reuters) – Alabama’s state Senate passed.

  • Israel regulator warns of medical cannabis bubble, eyes Australia pact

    JERUSALEM (Reuters) – Medical cannabis could.

  • U.S. measles outbreak grows with 75 new cases, mostly in New York

    (Reuters) – U.S. health authorities recorded.

  • Teva Pharm CFO says company did not conspire to fix prices

    FILE PHOTO: The logo of Teva.

  • U.S. states accuse Teva, other drugmakers, of price-fixing: lawsuit

    WASHINGTON (Reuters) – U.S. states filed.

  • Exclusive: Philip Morris suspends social media campaign after Reuters exposes young ‘influencers’

    (Reuters) – Cigarette maker Philip Morris.

  • Hong Kong reports African swine fever case

    HONG KONG (Reuters) – Hong Kong.

  • Alabama Senate delays vote on strict anti-abortion bill

    (Reuters) – Alabama’s state Senate on.

  • Denver votes to become first U.S. city to decriminalize ‘magic mushrooms’

    Psilocybin or “magic mushrooms” are seen.

  • AstraZeneca-Daiichi Sankyo breast cancer drug shows promise

    The company logo for pharmaceutical company.

  • Denver to vote on decriminalizing ‘magic mushrooms’

    FILE PHOTO: Boxes containing magic mushrooms.

  • Trans teens face higher sexual assault risk when schools restrict bathrooms

    (Reuters Health) – Transgender adolescents may.

  • U.S. doctors use medical records to fight measles outbreak

    CHICAGO (Reuters) – U.S. doctors are.

  • UK’s Vectura wins patent infringement case against GlaxoSmithKline in U.S

    (Reuters) – British drugmaker Vectura Group.

  • Tyson Foods recalls almost 12 million pounds of chicken strips over contamination fears

    (Reuters) – Tyson Foods Inc significantly.

  • Monstrous rumors stoke hostility to Pakistan’s anti-polio drive

    PESHAWAR, Pakistan (Reuters) – His bearded.

  • U.S. health agency finalizes conscience and religious freedom rule

    WASHINGTON (Reuters) – The U.S. Department.

  • Medication use drops when local drugstores close

    (Reuters Health) – People are less.

  • EPA says popular weed killer glyphosate is not a carcinogen

    CHICAGO (Reuters) – The U.S. Environmental.

  • Novartis’s Sandoz strikes deal for biosimilar of Herceptin

    FILE PHOTO: Swiss drugmaker Novartis’ logo.

  • U.S. measles outbreak triggers quarantine at two Los Angeles universities

    LOS ANGELES (Reuters) – A nationwide.

  • U.S. measles outbreak raises questions about immunity in adults

    (Reuters) – Adults in the United.